“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
The US Food and Drug Administration (FDA) has approved Takeda's new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in ...
Gammagard Liquid is a brand-name infusion prescribed for certain rare immune conditions. Gammagard Liquid contains the active ingredient immune globulin (human). Gammagard Liquid has boxed warnings. A ...
Immune globulin (human) 10% (100mg/mL); soln for IV or SC infusion; contains ≤2mcg/mL immunoglobulin A (IgA); preservative-, sucrose- and latex-free. Gammagard Liquid ERC supplies a broad spectrum of ...
CHICAGO (July 30, 2008) -- NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous ...
− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged ...
“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
Immune globulin (human) 10% (100mg/mL); liq for IV or SC infusion; preservative-, sucrose- and latex-free. Gammagard Liquid supplies a broad spectrum of opsonizing and neutralizing IgG antibodies ...
GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results